Most recent articles by:

Jessicca Rege

Jessicca Rege serves as Vice President, Clinical Research Oncology at Alkermes, where she is responsible for establishing the company’s immuno-oncology development strategy and overseeing the execution of its global clinical trials. Dr. Rege joined Alkermes in 2020, bringing with her more than 15 years of experience in research, clinical development and global medical affairs. She previously held roles of increasing responsibility at Bristol-Myers Squibb, Eisai, Daichi Sankyo and Boehringer Ingelheim. Dr. Rege earned a Bachelor of Science from Carson-Newman, and holds both a Master of Science in Physiology and a Ph.D. in Pharmaceutical Sciences from Virginia Commonwealth University. She completed her postdoctoral fellowship in pediatric leukemia at the University of Pennsylvania’s Children’s Hospital of Philadelphia
- Advertisement -

Addressing Unmet Need in Treatment-Resistant Cancers Through Purposeful R&D

Whenever I’m asked about what drives my passion for cancer treatment and oncology R&D, my answer is simple: with every innovation, we’re...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm
- Advertisement -